Spartan 3 (Mod GRF 1-29/CJC-1295 No Dac + GHRP-6)
|Molar Mass||873.032 g·mol−1|
|Mod grf 1-29/CJC-1295 No Dac|
|Molar Mass||3357.93 g·mol−1|
Spartan 3, a research peptide combination of Mod GRF 1-29 (CJC-1295 No Dac) and GHRP-6, holds promise as a valuable tool for scientific inquiry. Strictly designated for research purposes, this peptide blend is of interest to researchers exploring its potential applications within controlled laboratory settings.
Spartan 3 is characterized by its unique composition, combining Mod GRF 1-29 (CJC-1295 No Dac) and GHRP-6. Each component contributes distinct properties, making this combination a subject of scientific interest for researchers studying growth hormone regulation and related physiological processes.
The primary application of Spartan 3 in research lies in its potential to modulate growth hormone levels and influence various aspects of metabolism. Researchers utilize this peptide blend to investigate its impact on growth hormone deficiency, obesity, and the potential synergistic effects arising from the combination.
Spartan 3 is investigated for potential synergistic effects resulting from the combination of Mod GRF 1-29 (CJC-1295 No Dac) and GHRP-6. Researchers explore how these peptides, when combined, may exert complementary actions to enhance the overall regulatory effects on growth hormone secretion.
CJC 1295 No DAC and Treatment of Growth Hormone Deficiency
Scientific inquiries focus on the specific benefits of CJC-1295 No Dac in addressing growth hormone deficiency. Researchers aim to elucidate the peptide’s role in regulating growth hormone levels and its potential therapeutic applications in cases of deficiency.
GHRP-6 and Obesity
Studies into the role of GHRP-6 in addressing obesity provide a notable avenue for research. Investigators explore the potential of GHRP-6 to influence metabolic processes, specifically its impact on appetite regulation and fat metabolism.
In summary, Spartan 3 (Mod GRF 1-29/CJC-1295 No Dac + GHRP-6) emerges as a multifaceted research tool, offering researchers the opportunity to explore synergistic effects and individual benefits of its components. This peptide combination holds the potential to contribute to the understanding of growth hormone regulation and related therapeutic avenues.
- Maletínská L, Matyšková R, Maixnerová J, Sýkora D, Pýchová M, Spolcová A, Blechová M, Drápalová J, Lacinová Z, Haluzík M, Zelezná B. The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol. 2011 Aug 22;343(1-2):55-62. doi: 10.1016/j.mce.2011.06.006. Epub 2011 Jun 17. Erratum in: Mol Cell Endocrinol. 2012 Jan 2;348(1):344. PMID: 21704671. [Read More].
- Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019 Jun;11(6):804-812. doi: 10.1002/dta.2554. Epub 2018 Dec 25. PMID: 30489688. [Read More].